CONTEXT: Alström syndrome (AS) is a monogenic form of infancy-onset obesity and insulin resistance, caused by ALMS1 mutations. The natural history of the insulin resistance is unknown, in particular how this relates to changes in body composition. It is also unclear how ALMS1 mutations relate to the characteristic phenotype. OBJECTIVES: Our objectives were to characterize body composition and metabolic parameters, to establish ALMS1 mutation spectrum of United Kingdom AS patients, and to determine whether a genotype-phenotype correlation exists. DESIGN AND PATIENTS: We conducted a cross-sectional cohort study of 12 unrelated subjects with AS. Age-standardized body composition was assessed by anthropometry and dual-energy x-ray absorptiometry and insulin sensitivity by homeostasis model assessment. The exons and intron-exon boundaries of ALMS1 were directly sequenced. SETTING: The study was performed during the annual Alström Syndrome UK multidisciplinary screening clinic. RESULTS: AS patients have early-onset obesity, but body mass index, waist circumference, and body fat from dual-energy x-ray absorptiometry were negatively correlated with age (r = -0.37, P = 0.2; r = -0.84, P = 0.002; and r = -0.6, P = 0.05). Despite this, insulin resistance increased, demonstrated by raised fasting insulin and fall in homeostasis model assessment insulin sensitivity with age (r = -0.64, P = 0.02). ALMS1 mutations were identified in 10 of 12 patients, with a potential founder mutation in exon 16 present in five [np 10775del (C); Del3592fs/ter3597]. No genotype-phenotype correlation was observed. CONCLUSIONS: We identified mutations in ALMS1 in more than 80% of patients with no genotype-phenotype correlation. In AS, severe childhood obesity, waist circumference, and body fat decrease with age, whereas insulin resistance increases. The abdominal obesity, insulin resistance, diabetes, hypertriglyceridemia, and hypertension suggest that AS could represent a monogenic model for the metabolic syndrome.
CONTEXT: Alström syndrome (AS) is a monogenic form of infancy-onset obesity and insulin resistance, caused by ALMS1 mutations. The natural history of the insulin resistance is unknown, in particular how this relates to changes in body composition. It is also unclear how ALMS1 mutations relate to the characteristic phenotype. OBJECTIVES: Our objectives were to characterize body composition and metabolic parameters, to establish ALMS1 mutation spectrum of United Kingdom AS patients, and to determine whether a genotype-phenotype correlation exists. DESIGN AND PATIENTS: We conducted a cross-sectional cohort study of 12 unrelated subjects with AS. Age-standardized body composition was assessed by anthropometry and dual-energy x-ray absorptiometry and insulin sensitivity by homeostasis model assessment. The exons and intron-exon boundaries of ALMS1 were directly sequenced. SETTING: The study was performed during the annual Alström Syndrome UK multidisciplinary screening clinic. RESULTS: AS patients have early-onset obesity, but body mass index, waist circumference, and body fat from dual-energy x-ray absorptiometry were negatively correlated with age (r = -0.37, P = 0.2; r = -0.84, P = 0.002; and r = -0.6, P = 0.05). Despite this, insulin resistance increased, demonstrated by raised fasting insulin and fall in homeostasis model assessment insulin sensitivity with age (r = -0.64, P = 0.02). ALMS1 mutations were identified in 10 of 12 patients, with a potential founder mutation in exon 16 present in five [np 10775del (C); Del3592fs/ter3597]. No genotype-phenotype correlation was observed. CONCLUSIONS: We identified mutations in ALMS1 in more than 80% of patients with no genotype-phenotype correlation. In AS, severe childhood obesity, waist circumference, and body fat decrease with age, whereas insulin resistance increases. The abdominal obesity, insulin resistance, diabetes, hypertriglyceridemia, and hypertension suggest that AS could represent a monogenic model for the metabolic syndrome.
Authors: Jan D Marshall; Pietro Maffei; Sebastian Beck; Timothy G Barrett; Richard B Paisey Journal: Eur J Hum Genet Date: 2011-04-27 Impact factor: 4.246
Authors: Jan D Marshall; Jean Muller; Gayle B Collin; Gabriella Milan; Stephen F Kingsmore; Darrell Dinwiddie; Emily G Farrow; Neil A Miller; Francesca Favaretto; Pietro Maffei; Hélène Dollfus; Roberto Vettor; Jürgen K Naggert Journal: Hum Mutat Date: 2015-05-18 Impact factor: 4.878
Authors: Jamal Mahamid; Avraham Lorber; Yoseph Horovitz; Stavit A Shalev; Gayle B Collin; Jürgen K Naggert; Jan D Marshall; Ronen Spiegel Journal: Pediatr Cardiol Date: 2012-03-24 Impact factor: 1.655
Authors: Vera Bettini; Pietro Maffei; Claudio Pagano; Sara Romano; Gabriella Milan; Francesca Favaretto; Jan D Marshall; Richard Paisey; Francesco Scolari; Nella A Greggio; Ilaria Tosetto; Jürgen K Naggert; Nicola Sicolo; Roberto Vettor Journal: Pediatr Diabetes Date: 2011-07-03 Impact factor: 4.866
Authors: Claudia Izzi; Pietro Maffei; Gabriella Milan; Regina Tardanico; Paolo Foini; Jan Marshall; Alessandra Marega; Francesco Scolari Journal: Kidney Int Date: 2011-03 Impact factor: 10.612
Authors: Sukanya Lodh; Timothy L Hostelley; Carmen C Leitch; Elizabeth A O'Hare; Norann A Zaghloul Journal: Hum Mol Genet Date: 2015-10-22 Impact factor: 6.150
Authors: Ni-Chung Lee; Jan D Marshall; Gayle B Collin; Jürgen K Naggert; Yin-Hsiu Chien; Wen-Yu Tsai; Wuh-Liang Hwu Journal: Am J Med Genet A Date: 2009-02-15 Impact factor: 2.802
Authors: Margaret A Loudon; Nicholas G Bellenger; Catherine M Carey; Richard B Paisey Journal: Orphanet J Rare Dis Date: 2009-06-10 Impact factor: 4.123